| 101 |
15544502 | An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. | 2004 |
1 |
| 102 |
15544507 | New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease. | 2004 |
3 |
| 103 |
15554751 | Rivastigmine in frontotemporal dementia: an open-label study. | 2004 |
2 |
| 104 |
15633941 | Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients. | 2004 Nov-Dec |
1 |
| 105 |
14535624 | Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. | 2003 |
1 |
| 106 |
14569643 | Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. | 2003 Sep-Oct |
1 |
| 107 |
14573772 | The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. | 2003 Nov |
1 |
| 108 |
14646612 | Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. | 2003 Nov-Dec |
1 |
| 109 |
14687441 | Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. | 2003 |
3 |
| 110 |
15088511 | [Acetylcholinesterase inhibitors]. | 2003 Jul |
1 |
| 111 |
24944370 | Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. | 2003 Apr |
1 |
| 112 |
11888271 | Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. | 2002 Mar 19 |
5 |
| 113 |
12018828 | The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. | 2002 Apr |
2 |
| 114 |
12111443 | Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. | 2002 Jul |
6 |
| 115 |
12139365 | The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. | 2002 Jun |
5 |
| 116 |
12139366 | Do cholinesterase inhibitors slow progression of Alzheimer's disease? | 2002 Jun |
3 |
| 117 |
12139367 | The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. | 2002 Jun |
1 |
| 118 |
12139368 | Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. | 2002 Jun |
2 |
| 119 |
12196650 | Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. | 2002 Aug 27 |
3 |
| 120 |
12240787 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. | 2002 |
3 |
| 121 |
12417373 | Rivastigmine in subcortical vascular dementia: an open 22-month study. | 2002 Nov 15 |
1 |
| 122 |
12450245 | The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. | 2002 Oct-Nov |
1 |
| 123 |
12454562 | Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. | 2002 Dec |
3 |
| 124 |
12469000 | Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. | 2002 Nov-Dec |
1 |
| 125 |
12548360 | Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. | 2002 Sep |
1 |
| 126 |
12636178 | The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. | 2002 |
1 |
| 127 |
12636181 | Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. | 2002 |
2 |
| 128 |
11336614 | Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders. | 2001 Apr |
2 |
| 129 |
11669506 | Maintaining cognitive function in Alzheimer disease: how effective are current treatments? | 2001 Aug |
1 |
| 130 |
11900310 | A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. | 2001 |
2 |
| 131 |
19811047 | Use of acetylcholinesterase inhibitors in Alzheimer's disease. | 2001 Sep |
1 |
| 132 |
10641971 | Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. | 2000 Jan |
1 |
| 133 |
10713582 | Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. | 2000 Mar |
2 |
| 134 |
11078030 | The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. | 2000 Oct |
1 |
| 135 |
11186600 | RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy? | 2000 Oct-Dec |
1 |
| 136 |
11256231 | Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. | 2000 Oct |
2 |
| 137 |
10362894 | A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). | 1999 Jul |
1 |
| 138 |
10363493 | [Treatment of Alzheimer's disease: acetylcholinesterase inhibitors]. | 1999 Apr |
1 |
| 139 |
10587286 | Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. | 1999 Dec |
4 |
| 140 |
11139819 | Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. | 1999 Oct |
3 |
| 141 |
9576639 | Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. | 1998 Apr |
1 |
| 142 |
9737824 | Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. | 1998 Jul-Aug |
12 |
| 143 |
9758554 | [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine]. | 1998 Aug |
1 |
| 144 |
9794506 | Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. | 1998 Oct |
1 |
| 145 |
15616667 | Alzheimer's disease therapy - an update. | 1998 May |
1 |
| 146 |
7884403 | Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. | 1994 |
1 |
| 147 |
8248533 | Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. | 1993 |
1 |
| 148 |
1776750 | Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. | 1991 |
1 |